Skip to content

Study on the comorbidity mechanism of coronary heart disease and rheumatoid arthritis

Study on the comorbidity mechanism of coronary heart disease and rheumatoid arthritis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040802
Enrollment
Unknown
Registered
2020-12-10
Start date
2019-01-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease, rheumatoid arthritis

Interventions

Sponsors

Tianjin University of Tradtional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria of the rheumatoid arthritis group were as follows: 1) patients who were treated in our hospital and obtained a definite diagnosis; 2) all examination items and signs were perfect; 3) they were in good health and did not have heart, liver, kidney and other systemic diseases; 4) they were between 35 and 65 years old; and 5) no metabolic diseases. The inclusion criteria of coronary heart disease group were: 1) patients who were treated in our hospital and obtained a definite diagnosis; 2) all examination items and signs were perfect; 3) in good health without metabolic diseases; 4) between 35-65 years of age; and 5) no autoimmune diseases.

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients with rheumatoid arthritis 1) Patients with severe joint deformity; 2) patients with other rheumatic diseases such as systemic lupus erythematosus, Sjogren's syndrome and knee osteoarthritis; 3) patients with metabolic diseases such as heart, brain, liver, kidney and other systems; 4) patients who had taken drugs to treat RA before the study. Exclusion criteria for patients with coronary heart disease 1) Patients with persistent atrial fibrillation, dilated cardiomyopathy, cardiac insufficiency; 2) patients with severe electrolyte disorders, malignant tumors, severe valvular disease; 3) patients with autoimmune diseases; 4) patients with other organic lesions or other metabolic diseases; 5) patients who had taken CHD improvement drugs before the study.

Design outcomes

Primary

MeasureTime frame
Erythrocyte sedimentation rate;platelet count;Rheumatism;C-reactive protein;

Countries

China

Contacts

Public ContactYubo Li

Tianjin University of Tradtional Chinese Medicine

yaowufexi001@sina.com+86 15332130770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026